Methods: TNFRSF13B DNA Sequencing Test was performed by LabCorp and Correlagen Diagnostics on family members of two families with CVID. The coding sequence of TNFRSF13Bwas amplified by PCR, and each PCR product then sequenced bi-directionally using the Sanger sequencing methodology.
Results: We investigated two families with CVID and identified the c.81G>A TNFRSF13B homozygous mutation in two siblings of Family A and the father and two children of Family B. There was an additional c.674a>G heterozygous mutation identified in Family A. Neither of these mutations have been previously identified to be associated with CVID, they were both labeled having as unclear significance for CVID thus the test was inconclusive.
Conclusions: We believe that in addition to the six already recognized mutations in TACI that are linked to CVID, the c.81G>A TNFRSF13B homozygous mutation and the TNFRSF13B c.674a>G heterozygous mutation are linked to CVID as well.